Key decision makers in drug development will discuss PK/PD testing, safety pharmacology strategies and immunogenicity challenges in biologics development. Presentations will also explore the latest methods to improve decision making in drug development; from advances in biomarker technology, to the integration of safety studies earlier in the pipeline.